Heterozygous mutations in FOXP2, which encodes a forkhead transcription factor, have been shown to cause developmental verbal dyspraxia and language impairment. FOXP2 and its closest homolog, FOXP1, are coexpressed in brain regions that are important for language and cooperatively regulate developmental processes, raising the possibility that FOXP1 may also be involved in developmental conditions that are associated with language impairment. In order to explore this possibility, we searched for mutations in FOXP1 in patients with intellectual disability (ID; mental retardation) and/or autism spectrum disorders (ASD). We first performed array-based genomic hybridization on sporadic nonsyndromic ID (NSID) (n ¼ 30) or ASD (n ¼ 80) cases. We identified a de novo intragenic deletion encompassing exons 4-14 of FOXP1 in a patient with NSID and autistic features. In addition, sequencing of all coding exons of FOXP1 in sporadic NSID (n ¼ 110) or ASD (n ¼ 135) cases, as well as in 570 controls, revealed the presence of a de novo nonsense mutation (c.1573C>T [p.R525X]) in the conserved forkhead DNA-binding domain in a patient with NSID and autism. Luciferase reporter assays showed that the p.R525X alteration disrupts the activity of the protein. Formal assessments revealed that both patients with de novo mutations in FOXP1 also show severe language impairment, mood lability with physical aggressiveness, and specific obsessions and compulsions. In conclusion, both FOXP1 and FOXP2 are associated with language impairment, but decrease of the former has a more global impact on brain development than that of the latter.
Developmental language disorders represent a heterogeneous group of conditions that are frequent but poorly understood. Although these disorders show high heritability, very little is known about the causative genes. FOXP2 (MIM 605317) represents an important entry point into the molecular basis of developmental language disorders. 1, 2 Patients heterozygous for mutations in FOXP2
show verbal dyspraxia (MIM 602081), which is characterized by impaired coordinated mouth movements that are required for speech, as well as variable impairment of expressive and receptive language, without consistent nonverbal cognitive deficits. Recent studies suggest that FOXP2 is also required for vocal learning in birds and that it might have played a role during the evolution of human language. [3] [4] [5] FOXP2 belongs to a subgroup of the FOX family of winged-helix/forkhead transcription factors, which also includes FOXP1 (MIM 605515), FOXP3 (MIM 300292), and FOXP4 (MIM 608924). 6 Several observations suggest that FOXP2 and its closest relative, FOXP1, may regulate common processes. For instance, FOXP1 and FOXP2 are expressed in distinct but also in overlapping regions of the developing bird, mouse, and human brain, including areas associated with the production and processing of vocalization and language. [7] [8] [9] [10] FOXP proteins act as transcriptional repressors by forming homo-or heterodimers. 9, 11, 12 Interestingly, FOXP1 and FOXP2 can physically interact in vitro, can repress the transcription of common targets in vivo by occupying the same binding sites, and cooperatively regulate lung and esophageal development in mice. 11, 13 Because FOXP1 and FOXP2 cooperate to control developmental processes, it was hypothesized that mutations in FOXP1 could likewise be associated with language impairment. 10, 14 However, sequencing of FOXP1 in a cohort of individuals with developmental verbal dyspraxia did not reveal any pathogenic mutations. 14 Another possibility is that FOXP1 disruption causes other developmental conditions that are associated with language impairment, such as intellectual disability (ID; mental retardation) and autism spectrum disorders (ASD [MIM 209850]). 15 In order to explore this possibility, we performed mutation analyses of FOXP1 in patients with ID and/or ASD. Because FOXP2 heterozygous mutations are sufficient to disrupt language development, we decided, likewise, to focus our attention on heterozygous mutations, which in the case of ID are more likely to arise de novo than to be transmitted. By analogy to the FOXP2 paradigm, we also restricted our analysis to patients without specific morphological abnormalities (referred to herein as having the nonsyndromic form of ID and ASD). We studied sporadic cases with nonsyndromic ID (NSID), ASD, or both NSID and ASD, most of which were of French Canadian origin. We chose to study sporadic cases to increase the likelihood of identifying de novo mutations. The NSID cases were selected with the use of previously described criteria. 16 The sporadic ASD patients were diagnosed according to DSM-IV criteria and were selected on the basis of a positive Autism Diagnostic Interview-Revised (ADI-R) and/or Autism Diagnostic Observation Schedule-Generic (ADOS-G). We used 570 healthy individuals as controls, including 285 French Canadians and 285 European individuals who were evaluated and found not to have cognitive dysfunction, neuropsychiatric symptoms, or family history of neuropsychiatric problems, as detailed elsewhere. 17 Blood samples were collected from all members of these cohorts and from their parents, with informed consent and after approval of the study by institutional ethics committees. Genomic DNA was extracted from blood samples with the Puregene kit (Gentra). Paternity and maternity of each NSID and ASD patient proband trio were confirmed with the use of six informative microsatellite markers. We initially determined whether FOXP1 is affected by copy number changes in 80 individuals from the sporadic ASD cohort (including 27 with documented ID), using Genome-Wide Human Affymetrix 5.0 SNP arrays, and in 30 individuals from the sporadic NSID cohort, using Affymetrix 6.0 SNP arrays. Both parents of each case were also studied with these arrays. We identified a de novo intragenic FOXP1 deletion in an NSID female patient (R0031608) (patient A). This~390 kb deletion (genomic region on chromosome 3:71114875-71504640; hg18) encompasses exons 4-14 of the longest isoform of FOXP1 (FOXP1a; Refseq no. NM_032682.4), including sequence corresponding to its translation initiation site as well as to leucine zipper and zinc finger domains that are important for FOXP1 dimerization and regulation of transcriptional activity ( Figure 1A) . 11, 13 Multiplex ligation-dependent probe amplification (MLPA) analysis of FOXP1 in patient A confirmed the loss of these exons ( Figure 1B) . No deletions encompassing FOXP1 exons were identified in the other tested patients or their parents, nor have any been reported in the Database of Genomic Variants, a large public repository of structural variations in population controls. 18 We next sequenced all the coding exons and intronexon boundaries of the longest FOXP1 isoform (FOXP1a; 16 coding exons) in 110 cases with NSID, 84 cases with ASD, and 51 cases with both NSID and ASD, as well as in 570 controls. We identified a de novo nonsense mutation, c.1573C>T (p.R525X), in a male patient with NSID and autism (R0024121) (patient B). This alteration abolishes the last 152 amino acids of FOXP1, including part of the forkhead DNA-binding domain (FHD) and a conserved nuclear localization signal (NLS) (Figure 2A) . 19, 20 The
FHDs of other FOXP proteins share more than 90% sequence identity with that of FOXP1 ( Figure 2B ). 21 Figure 2B ). 24, 25 Sequencing also revealed a heterozygous missense mutation, c.643C>A (p.P215A), in both an NSID patient (n ¼ 1/ 110) and a healthy individual (n ¼ 1/570). In the case of the NSID patient, the variant was transmitted from an unaffected parent, further supporting the notion that it is not pathogenic. This variant was also previously reported in an individual with developmental verbal dyspraxia and in a control sample.
14 Three additional hetero-
were detected in FOXP1, but these did not affect any known functional domains and were present only in our cohort of controls, indicating that they are not pathogenic. No other amino-acid-altering variants were identified in any of the screened individuals, including the 570 healthy controls. In order to test the effect of the p.R525X mutation on FOXP1 activity, we took advantage of the well-documented ability of FOXP1 to repress transcription from the SV40 promoter, which can be easily monitored with the use of a standard luciferase assay. 9, 20 The p.R525X mutation was introduced into the full-length coding sequence of the FOXP1 longest isoform (FOXP1a; obtained from Kazusa DNA Research Institute, Japan) and subcloned into the mammalian expression vector pcDNA4HisMax (Invitrogen). Human embryonic kidney (HEK) 293 cells were then cotransfected with the use of Fugene 6 (Roche) in 24-well plates, with 400 ng of pcDNA4HisMax without an insert or containing either the wild-type (WT) FOXP1 or the FOXP1-R525X cDNA, along with 50 ng of pGL3-promoter construct (Promega) (in which the SV40 promoter drives a firefly luciferase reporter). In order to account for variations in transfection efficiency and variation in cell number, cells were also cotransfected with 50 ng of a Renilla luciferase construct (pRL-TK; Promega) driven by the HSVthymidine kinase promoter, which is not affected by FOXP1. Cells were lysed 48 hr after transfection and quantified for firefly and Renilla luciferase activities with the use of the Dual Luciferase Reporter Assay System (Promega). As shown in Figure 2D , WT FOXP1 was found to significantly inhibit the firefly luciferase signal (~50% reduction; p < 0.001), as compared with an empty vector, whereas FOXP1-R525X failed to induce any reduction in luciferase levels, indicating that the p.R525X alteration impaired the FOXP1 ability to repress the SV40 promoter. . Each dot represents a SNP or a copy number marker, with normal copy number having a log2 ratio of~0 and deleted regions less than À1. The CNV analysis was performed according to the manufacturer's procedure with the use of the Affymetrix reference library, GenomeWideSNP_6.hapmap270.na30r1.a5, with a regional GC correction. The de novo deletion (chr3: 71109689-71508061; hg18) is boxed, and the only gene affected with this deletion, FOXP1, is shown.
(B) Mapping of FOXP1 deleted exons in patient A. Using MLPA analysis, 35 we mapped the deletion breakpoints between exon 4 and exon 14 of FOXP1. MLPA probes targeting 14 exons (Ex) of FOXP1 were custom designed with the ProSeek software. 36 These 14 probes were compared to two control probes on chromosome X and chromosome 1. MLPA was performed on 50 ng of genomic DNA. Probe amplification products were run on an ABI 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA). The data were analyzed with the GeneMapper software version 4.0 (Applied Biosystems). The dosage ratio (DR) was calculated as follows: DR ¼ (peak height FOXP1 / peak height chromosome 1 probe) in the patient carrying the deletion / (peak height FOXP1 / peak height chromosome 1 probe) in her unaffected mother, who has no copy number variation in FOXP1. The DR has a theoretical value of % 0.7 for a deletion, between 0.7 and 1.3 for a normal situation, and R 1. . Alignment of the conserved FHD region of the four members of the human FOXP family. Highlighted and underlined in red are residues that when mutated lead to human disease: p.R525X (current study) in NSID, autism, and language impairment; p.R553H in FOXP2 in severe congenital speech disorder; 24 and p.I363V, p.F371C/L, p.A384T, and p.R397T in FOXP3 in IPEX syndrome. 21 Amino acid identity and similarity are represented by asterisks (*) and dots (.), respectively. (C) Chromatograms corresponding to the FOXP1 de novo mutation (c.1573C>T [p.R525X]) identified in patient B. Wild-type (WT) and mutant (MT) FOXP1 DNA sequences are shown along with the corresponding amino acids. (D) Luciferase reporter assay assessing the impact of p.R525X on FOXP1 transactivation activity in transfected HEK293 cells. FOXP1 significantly inhibited pGL3-promoter (SV40) transcriptional activity (p < 0.001) as compared to empty vector (pcDNA4)-transfected cells only. In contrast, FOXP1-R525X failed to repress the pGL3-promoter activity. Results (mean 5 SEM of three independent experiments, each performed in triplicate) are shown as relative firefly luciferase activity, which is driven by SV40 promoter, normalized with Renilla luciferase, and driven by HSV-TK promoter activity. The control signal value (set to 100%) was obtained with cells transfected with the empty expression vector (pcDNA4HisMax) and both pGL3-promoter (firefly luciferase) and pRL-TK (Renilla luciferase) constructs.
protein, impaired DNA binding, as suggested from the crystal structure of the FOXP2 FHD, or a combination of both. Although mutant and WT proteins were detected at comparable levels in transfected HEK293 cells, we cannot also exclude the possibility that the p.R525X mutation induces nonsense-mediated decay of FOXP1 mRNA in the patient's cells ( Figure 2E ). Additional work is needed to address these mechanistic questions.
The phenotypes of both patients with de novo mutations in FOXP1 are summarized in Table 1 . Patients A and B were born from nonconsanguineous French Canadian parents after uneventful pregnancies and deliveries. Patient B was operated on for atresia of the midjejunum and midileum gut during the neonatal period. Their initial development was characterized by global delay, with severe language impairment. They started to walk between the ages of 18 and 20 mo. Patient A was not clearly pronouncing any word until 3 yrs of age and started to associate words at 4 yrs of age, whereas patient B said his first words at the age of 6 yrs. The patients exhibited no deficits of oromotor coordination that could explain this delay in learning to talk.
Patients A and B were assessed with the ADI-R and the ADOS-G at 6 yrs 8 mo and at 2 yrs 7 mo, respectively. Despite some autistic features in reciprocal social interaction (social avoidance with peers and decreased inhibition with adults) and restricted interests and repetitive behaviors (delayed echolalia and stereotyped language, selfinjury, perceptual fixations), patient A would not have been considered as being autistic because of subthreshold scores in the communication area. In contrast, patient B showed scores above the diagnostic threshold for autism in all areas.
Patients A and B were evaluated with a series of cognitive and behavioral assessment tools at 15 and 9 yrs of age, respectively. Assessment with the Leiter International Performance Scale-R (Brief IQ), an estimate of nonverbal intellectual functioning, revealed ID in the mild to moderate range. Results from the Vineland Adaptive Behavior Scale were consistent with the presence of ID in both patients, showing severe deficits in adaptive behaviors across the range of subscales (communication, daily living skills, socialization). Formal testing of patient A via the Clinical Evaluation for Language Fundamentals confirmed the presence of severe language impairment. Specifically, expressive language was severely limited, with oral communication characterized by single words or very short, simple sentences. Expressive vocabulary, equivalent to about 4.5 yrs, was slightly better than other expressive skills, such as morphology and repetition of increasingly complex sentences (both below 4 yrs) but was nonetheless mostly limited to relatively simple, frequent words. In several tests, she gave responses to expressive language items by miming the required words, indicating good comprehension of the question but an inability to produce the answer verbally. In support of this, receptive language abilities were somewhat more developed, as indicated by her understanding of a number of more complex relational and numerical concepts. Assessment of patient B with the Preschool Language Scale also confirmed severe language impairment. In terms of expressive communication, he scored at an age equivalence of 1 yr 11 mo. He had a range of about 100 words in his vocabulary and communicated with single words or short sentences (two to three words). In contrast, he was able to understand more complex relational concepts and performed at an age equivalence of 3 yrs 7 mo in auditory comprehension tasks.
Both patients also showed a particular behavioral profile. Clinically significant problems were noted on the Vineland Maladaptive Behavior scale for patient A and were characterized by both internalizing (e.g., social withdrawal, anxiety) and externalizing (e.g., impulsivity, mood lability, temper tantrums, sulking, disobedience, physical aggression) behaviors. Parent responses on the Aberrant Behavior Checklist also indicated the presence of behavioral problems in both patients. In patient A, irritability was rated as the most significant problem, with all other problem scales (lethargy, stereotypy, hyperactivity, inappropriate speech) reaching clinically significant levels. Similarly, patient B had significantly elevated problems on the irritability, stereotypy, and hyperactivity subscales and clinically significant speech problems. A number of specific obsessions and compulsions (e.g., looking in mirrors, touching people's hair, nail biting, removing silicone in the house, hoarding objects) were described by the parents and confirmed via the Repetitive Behavior Scale. On this scale, ritualistic, restricted, and ''sameness'' behavior were most often reported for patient A (e.g., mealtime and bedtime rituals, rigid routines, listens to the same music continuously, strong attachment to specific objects). Stereotyped and self-injurious behavior (e.g., turning in circles, spinning objects, hitting and biting self) were also reported for patient B.
In summary, we report two patients with de novo deleterious intragenic mutations in FOXP1. These patients share strikingly similar phenotypes, including mild to moderate ID with severe language impairment, autism and /or autistic features, mood lability with physical aggressiveness, and specific obsessions and compulsions. The patients with FOXP1 disruption described herein do not show verbal dyspraxia, but their phenotype nevertheless overlaps with that of patients with FOXP2 disruption to the extent that they also show language impairment. Two other patients with de novo deletions encompassing FOXP1 were recently described. 26, 27 These patients, who (E) Immunoblot performed on total protein extracts from HEK293 cells transfected with pcDNA4-HisMax-based constructs expressing FOXP1 or FOXP1-R525X in frame with an N-terminal Xpress tag, as described in the text. Proteins were resolved on SDS-PAGE, and FOXP1 and FOXP1-R525X were detected with the use of a monoclonal antibody against the N-terminal Xpress tag (Invitrogen). The blot was stripped and probed with an anti-alpha-tubulin antibody (Abcam) as an internal loading control.
were less than 4 yrs of age when studied, showed developmental and speech delay, but formal cognitive or behavioral evaluation could not be performed. In one case, the deletion spans 750 kb and affects three other genes whereas in the other case, the deletion spans 1 Mb and extends over 500 kb on the 3 0 end of FOXP1. Even though this latter deletion does not affect any other known genes, the possibility that it encompasses elements that are important for the expression of genes located in its vicinity cannot be ruled out. Nevertheless, these cases reinforce our conclusion that FOXP1 haploinsufficiency affects cognitive development. Although an association between vitiligo (MIM 193200), an autoimmune form of skin depigmentation, and an intronic variant in FOXP1 was recently reported, 28 none of our patients displayed signs of such a condition. Although FOXP1 and FOXP2 can cooperate to regulate transcription and are both associated with language impairment, FOXP1 disruption appears to have a more global impact on brain development than FOXP2 disruption. The difference between the phenotypic consequence of FOXP1 and FOXP2 haploinsufficiency might be explained at least in part by some difference in their expression patterns. impairment and autism. [29] [30] [31] [32] It is tempting to speculate that FOXP1 homodimers or FOXP1-FOXP2 heterodimers also regulate CNTNAP2 expression and that FOXP1 haploinsufficiency affects language development and possibly causes ID and autism by disrupting this regulatory interaction. FOXP1 and FOXP2 thus represent interesting entry points for dissecting the molecular mechanisms underlying neurodevelopmental disorders such as ID, autism, and language impairment.
